hVIVO plc to present at the World Vaccine Congress, Washington D.C.

hVIVO plc (Euronext / LON:HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that Dr Andrew Catchpole, Chief Scientific Officer, will be delivering a presentation at the World Vaccine Congress, Washington D.C., United States. Full details of the presentation are included below:

TitleChallenge Studies – can the results be expected to mimic field trial data?
Date/TimeWednesday 5 April 2023, 17.10 (ET)

The World Vaccine Congress will take place at the Walter E. Washington Convention Center in Washington D.C. between 3-6 April 2023. hVIVO will be at booth 813 during the congress for potential partnering discussions.

The World Vaccine Congress, organised by Terrapin, is the largest and most established meeting dedicated to vaccines and has run for 23 years. From basic research to commercial manufacture, the event covers the whole vaccine value chain, with hundreds of speakers and thousands of attendees from leading global vaccines developers, academia and policymakers.

More information about the event, including attendance, can be found here.

To request meetings with hVIVO at the World Vaccine Congress, interested parties should register with Swapcard and use the following link or by emailing bd@hvivo.com

Yamin ‘Mo’ Khan, Chief Executive Officer at hVIVO, said: “I am delighted that Andrew will be presenting at the largest vaccine event of the year amongst many other notable speakers, discussing the significant value of human challenge trial data. As the global leader in conducting human challenge trials to test vaccines and antivirals for infectious and respiratory diseases, we are looking forward to participating in roundtable discussions and sharing insights into how human challenge trials can accelerate the drug development process.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO Capital Markets Day: Key insights and developments

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Key differences between Clinical Trials and Clinical Studies

    Understanding the distinction between clinical trials and clinical studies is vital in the realm of medical research. While all clinical trials fall under the broader category of clinical studies, the two are not synonymous. Clinical trials

    hVIVO plc

    The role of healthy volunteers in clinical trials

    Clinical trials are essential in bringing new drugs, treatments, and interventions to market. These trials progress through several phases, with each stage serving a specific purpose. In the early phases, particularly the first phase, healthy volunteers

    hVIVO plc

    What to expect when participating in clinical trials

    When you volunteer for a clinical trial, it’s essential to manage your expectations, understanding both the potential benefits and risks involved. Awareness of the side effects associated with clinical trials can better prepare you for the

    hVIVO plc

    Understanding placebo use in clinical trials

    Various types of clinical trials require participants to help advance medical knowledge, improve patient care, and develop new treatments. A common element in these trials is the use of placebos. Placebos, substances with no therapeutic effect,

    hVIVO plc

    Phases of clinical trials: A journey to market approval

    When a pharmaceutical company aims to introduce a new product to the market, it must first navigate a series of clinical trials, consisting of four distinct phases. These phases are crucial for assessing the intervention’s efficacy

    hVIVO plc

    New era in virus testing at Canary Wharf

    Between J.P. Morgan’s London headquarters and the Mastercard office in Canary Wharf lies an unassuming building that is home to some of the most transmissible viruses known to science. This is where hVIVO, a contract research

    hVIVO plc

    Understanding the different types of Clinical Trials

    Clinical trials are essential for advancing medicine, enhancing drug discovery, and improving patient safety. There are two main types of clinical trials: observational and interventional. Understanding these types helps researchers conduct thorough, safe, effective, and compliant

    hVIVO plc

    Hvivo reports record revenue in first half of the year

    Hvivo, a Dublin and London-listed pharmaceutical services company, reported a record revenue for the first half of the year, continuing its momentum in the market. Specialising in testing infectious and respiratory disease products, Hvivo announced that

    hVIVO plc

    hVIVO materially increases revenue, further improving margins

    hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has provided a trading update for the six-month period ended 30 June 2024. Highlights

    hVIVO plc

    The importance of clinical trials in medical research

    Clinical trials are a critical component of medical research, involving the testing of pharmaceutical drugs, medical devices, or other treatments on human participants to evaluate their efficacy and safety. These trials play a crucial role in

    hVIVO plc

    Accelerating vaccine development to combat the tripledemic

    The recent rise of the “tripledemic” – the simultaneous spread of the influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) – is posing significant risks, especially to older adults and those with chronic conditions or compromised